Pfizer aims to make 10-20 million doses of a coronavirus vaccine the company is developing with Germany’s BioNtech by the end of 2020 for emergency use depending on trial results, the U.S. drugmaker’s vaccines head said.
Less than one month after Johnson & Johnson identified a lead vaccine candidate against COVID-19, the life sciences giant announced an agreement with Emergent BioSolutions to support the manufacturing needs for the potential medication.
World leaders pledged to accelerate work on tests, drugs and vaccines against COVID-19 and to share them around the globe, but the United States did not take part in the launch of the World Health Organization (WHO) initiative.
The second round of dosing in healthy Seattle volunteers for Moderna’s mRNA-1273 vaccine candidate against COVID-19 has begun. The Phase 1 study is being conducted by the National Institutes of Health (NIH).
Bay Area-based Vaxart Inc. obtained positive pre-clinical results for the company’s COVID-19 vaccine candidates, with several of them generating immune responses in all tested animals after a single dose.
A million doses of a potential COVID-19 vaccine being developed by British scientists are already being manufactured and will be available by September 2020, even before trials prove whether the shot is effective, the team said.
U.S. health agencies, the European drug regulator and 16 top drugmakers will collaborate on vaccine and drug development efforts to fight the coronavirus pandemic, the U.S. National Institutes of Health said.
Ligandal is reportedly the only company developing a prospective “antidote” and vaccine in a single platform for COVID-19, with an approach that could actually help eliminate the virus from an already-infected host, while also bolstering the immune response.
California-based Dynavax Technologies entered the race alongside Sinovac Biotech to develop a vaccine candidate against COVID-19.
Cambridge, Massachusetts-based Moderna is one of the first companies to move a vaccine against COVID-19 into clinical trials.
